Published in Transplantation on April 27, 2014
Memory B cells in transplantation. Transplantation (2015) 0.82
Introduction of a Framework for Dynamic Knowledge Representation of the Control Structure of Transplant Immunology: Employing the Power of Abstraction with a Solid Organ Transplant Agent-Based Model. Front Immunol (2015) 0.77
Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. World J Gastroenterol (2015) 0.76
Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol (1999) 11.94
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature (2008) 10.80
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med (2011) 7.29
Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A (2012) 3.27
Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant (2004) 3.25
Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis (2009) 3.12
Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant (2005) 2.70
De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant (2011) 2.28
Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol (2008) 1.96
Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest (2011) 1.94
Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res (2004) 1.90
Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther (2011) 1.81
Protective role of gamma interferon during the recall response to influenza virus. J Virol (1998) 1.55
Efficacy of influenza A H1N1/2009 vaccine in hemodialysis and kidney transplant patients. Clin J Am Soc Nephrol (2011) 1.26
Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am J Kidney Dis (2009) 1.22
Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant (2009) 1.20
Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant (2009) 1.20
Systems vaccinology: learning to compute the behavior of vaccine induced immunity. Wiley Interdiscip Rev Syst Biol Med (2011) 1.19
Changing attitudes toward influenza vaccination in U.S. Kidney transplant programs over the past decade. Clin J Am Soc Nephrol (2010) 1.08
Effects of influenza immunization on humoral and cellular alloreactivity in humans. Transplantation (2010) 1.02
Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant (2011) 0.98
The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis (1996) 0.95
Immunosuppression for lung transplantation. Proc Am Thorac Soc (2009) 0.94
Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naïve T cells into cytokine-producing mature T cells. PLoS One (2012) 0.92
One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. Vaccine (2012) 0.91
Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant (2004) 0.91
Serologic vaccination response after solid organ transplantation: a systematic review. PLoS One (2013) 0.89
Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients. Bone Marrow Transplant (2005) 0.89
Drug insight: maintenance immunosuppression in kidney transplant recipients. Nat Clin Pract Nephrol (2006) 0.88
Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother (2003) 0.86
Reduced incidence of pneumonia in influenza-vaccinated solid organ transplant recipients with influenza disease. Clin Microbiol Infect (2012) 0.86
Protective cellular immunity against influenza virus induced by plasmid inoculation of newborn mice. Dev Immunol (1998) 0.82
Impact of adjuvanted H1N1 vaccine on cell-mediated rejection in heart transplant recipients. Am J Transplant (2011) 0.82
Deficient long-term response to pandemic vaccine results in an insufficient antibody response to seasonal influenza vaccination in solid organ transplant recipients. Transplantation (2012) 0.81
Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients. Med Microbiol Immunol (2012) 0.81
Influenza vaccination in solid-organ transplant recipients. Curr Opin Organ Transplant (2012) 0.81
Influenza vaccines in the setting of solid-organ transplantation: are they safe? Curr Opin Infect Dis (2012) 0.78
Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science (2005) 17.19
Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med (2009) 15.02
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature (2008) 10.80
Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science (2009) 8.61
A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science (2007) 8.38
Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol (2005) 7.88
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med (2011) 7.29
Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl Acad Sci U S A (2006) 6.35
Transmission of equine influenza virus to dogs. Science (2005) 6.11
Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med (2015) 6.04
Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998. J Infect Dis (2002) 5.92
Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell (2006) 5.39
Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med (2015) 4.90
Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol (2002) 4.87
H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog (2008) 4.79
Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J Virol (2006) 4.00
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature (2010) 3.96
Human HA and polymerase subunit PB2 proteins confer transmission of an avian influenza virus through the air. Proc Natl Acad Sci U S A (2009) 3.91
Contemporary North American influenza H7 viruses possess human receptor specificity: Implications for virus transmissibility. Proc Natl Acad Sci U S A (2008) 3.45
Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc (2009) 3.30
Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A (2012) 3.27
Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis (2005) 3.20
Risk factors associated with subclinical human infection with avian influenza A (H5N1) virus--Cambodia, 2006. J Infect Dis (2009) 3.05
Characterization of highly pathogenic H5N1 avian influenza A viruses isolated from South Korea. J Virol (2005) 2.97
High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire. Nat Biotechnol (2013) 2.81
Past, present, and possible future human infection with influenza virus A subtype H7. Emerg Infect Dis (2009) 2.80
Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature (2013) 2.80
NS1 protein of influenza A virus inhibits the function of intracytoplasmic pathogen sensor, RIG-I. Am J Respir Cell Mol Biol (2006) 2.78
Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus. Proc Natl Acad Sci U S A (2008) 2.72
KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int (2009) 2.72
Lineage structure of the human antibody repertoire in response to influenza vaccination. Sci Transl Med (2013) 2.71
The ferret as a model organism to study influenza A virus infection. Dis Model Mech (2011) 2.68
Isolation and characterization of avian influenza viruses, including highly pathogenic H5N1, from poultry in live bird markets in Hanoi, Vietnam, in 2001. J Virol (2005) 2.51
Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol (2006) 2.47
Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response. Immunol Rev (2008) 2.41
Influenza: propagation, quantification, and storage. Curr Protoc Microbiol (2006) 2.36
Reassortment between avian H5N1 and human H3N2 influenza viruses in ferrets: a public health risk assessment. J Virol (2009) 2.33
Pathogenesis of avian influenza (H7) virus infection in mice and ferrets: enhanced virulence of Eurasian H7N7 viruses isolated from humans. J Virol (2007) 2.30
Effect of receptor binding domain mutations on receptor binding and transmissibility of avian influenza H5N1 viruses. Virology (2011) 2.28
Highly pathogenic avian influenza H5N1 viruses elicit an attenuated type i interferon response in polarized human bronchial epithelial cells. J Virol (2007) 2.23
The zinc finger transcriptional repressor Blimp1/Prdm1 is dispensable for early axis formation but is required for specification of primordial germ cells in the mouse. Development (2005) 2.23
Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med (2008) 2.21
Human immunoglobulin selection associated with class switch and possible tolerogenic origins for C delta class-switched B cells. J Clin Invest (2004) 2.21
Mature B cells class switched to IgD are autoreactive in healthy individuals. J Clin Invest (2007) 2.18
Influenza A virus (H3N8) in dogs with respiratory disease, Florida. Emerg Infect Dis (2008) 2.12
Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet (2006) 2.10
Should all living donors be treated equally? Transplantation (2002) 2.08
DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis (2007) 2.02
Lack of evidence of avian-to-human transmission of avian influenza A (H5N1) virus among poultry workers, Kano, Nigeria, 2006. J Infect Dis (2007) 1.98
Receptor specificity and transmission of H2N2 subtype viruses isolated from the pandemic of 1957. PLoS One (2010) 1.95
Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest (2011) 1.94
The Mx1 gene protects mice against the pandemic 1918 and highly lethal human H5N1 influenza viruses. J Virol (2007) 1.93
Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine (2007) 1.89
Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis (2009) 1.88
DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis (2002) 1.88
Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. J Exp Med (2008) 1.88
Intricate targeting of immunoglobulin somatic hypermutation maximizes the efficiency of affinity maturation. J Exp Med (2005) 1.85
Pregnancy in recipients of solid organs--effects on mother and child. N Engl J Med (2006) 1.84
Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int (2003) 1.83
Pathogenesis of pandemic influenza A (H1N1) and triple-reassortant swine influenza A (H1) viruses in mice. J Virol (2010) 1.79
Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis (2006) 1.78
Polygenic virulence factors involved in pathogenesis of 1997 Hong Kong H5N1 influenza viruses in mice. Virus Res (2007) 1.77
Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J Virol (2012) 1.74
Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol (2009) 1.73
Influenza virus aerosol exposure and analytical system for ferrets. Proc Natl Acad Sci U S A (2011) 1.70
Use of animal models to understand the pandemic potential of highly pathogenic avian influenza viruses. Adv Virus Res (2009) 1.67
Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis (2004) 1.66
Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine (2006) 1.66
Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol (2011) 1.62
Glycemic control promotes pancreatic beta-cell regeneration in streptozotocin-induced diabetic mice. PLoS One (2010) 1.58
A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One (2010) 1.57
Lack of evidence for human-to-human transmission of avian influenza A (H9N2) viruses in Hong Kong, China 1999. Emerg Infect Dis (2002) 1.54
Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4. Immunity (2013) 1.52
Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation. Am J Transplant (2005) 1.52
Serum antibody response to matrix protein 2 following natural infection with 2009 pandemic influenza A(H1N1) virus in humans. J Infect Dis (2013) 1.50
Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J Exp Med (2013) 1.47
Ocular infection of mice with influenza A (H7) viruses: a site of primary replication and spread to the respiratory tract. J Virol (2009) 1.47
The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine (2011) 1.44
Transforming growth factor-β: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis. PLoS Pathog (2010) 1.44
High abundance of plasma cells secreting transglutaminase 2-specific IgA autoantibodies with limited somatic hypermutation in celiac disease intestinal lesions. Nat Med (2012) 1.44
Successful retransplantation after renal allograft loss to polyoma virus interstitial nephritis. Transplantation (2002) 1.43
Influenza A virus transmission: contributing factors and clinical implications. Expert Rev Mol Med (2010) 1.41
Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection. J Virol (2010) 1.40
Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J Virol Methods (2008) 1.39
Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard. Vaccine (2011) 1.37
Pathogenesis and transmission of triple-reassortant swine H1N1 influenza viruses isolated before the 2009 H1N1 pandemic. J Virol (2010) 1.35
Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine. Virology (2003) 1.35
Mice lacking both TNF and IL-1 receptors exhibit reduced lung inflammation and delay in onset of death following infection with a highly virulent H5N1 virus. J Infect Dis (2010) 1.33
Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. PLoS One (2009) 1.33
Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding. J Virol (2009) 1.32
Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One (2009) 1.30
Myc stimulates B lymphocyte differentiation and amplifies calcium signaling. J Cell Biol (2007) 1.29
Pathogenesis, transmissibility, and ocular tropism of a highly pathogenic avian influenza A (H7N3) virus associated with human conjunctivitis. J Virol (2013) 1.27